Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI105760

Studies on manganese: III. The biological half-life of radiomanganese in man and factors which affect this half-life

John P. Mahoney and Walter J. Small

Research Laboratory, Carney Hospital, Boston, Massachusetts

Find articles by Mahoney, J. in: PubMed | Google Scholar

Research Laboratory, Carney Hospital, Boston, Massachusetts

Find articles by Small, W. in: PubMed | Google Scholar

Published March 1, 1968 - More info

Published in Volume 47, Issue 3 on March 1, 1968
J Clin Invest. 1968;47(3):643–653. https://doi.org/10.1172/JCI105760.
© 1968 The American Society for Clinical Investigation
Published March 1, 1968 - Version history
View PDF
Abstract

The biological half-life of manganese and some factors influencing it have been studied in man. The disappearance of manganese from the body in normal subjects is described by a curve having two exponential components. An average of 70% of the injected material was eliminated by the “slow” pathway. The half-time characterizing this component showed a small variation in normal subjects and had an average value of 39 days. The half-time for the “fast” component also showed a small variation and had an average value of 4 days.

In a normal subject presumed to have a low manganese intake due to a voluntary low caloric intake, the percentage eliminated by the slow pathway increased to 84% and the half-time characterizing the pathway increased to 90 days. The half-time of the “fast” component was the same as for the normal group. 2 months after initiation of the study in this subject, a large “flushing” dose of manganese markedly increased the elimination rate which was described by a single exponential curve.

A mildly iron-deficient subject showed a marked decrease in the percentage of manganese eliminated by the “slow” pathway accompanied by a less dramatic decrease in the half-time characterizing this pathway. Oral iron therapy, which corrected the mild anemia, caused a decrease in the elimination rate and the altered curve was described by a single exponential component.

Preloading two subjects with manganese resulted in a great decrease in the fraction eliminated by the “slow” pathway with less effect on the half-time. The subject with the largest preloading dose showed no “slow” component at all.

Observations on the red cells of some of these subjects showed that a small but definite fraction was incorporated into the erythrocytes.

In the mildly iron-deficient subject, our observations suggest an interrelationship between manganese and iron metabolism.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 643
page 643
icon of scanned page 644
page 644
icon of scanned page 645
page 645
icon of scanned page 646
page 646
icon of scanned page 647
page 647
icon of scanned page 648
page 648
icon of scanned page 649
page 649
icon of scanned page 650
page 650
icon of scanned page 651
page 651
icon of scanned page 652
page 652
icon of scanned page 653
page 653
Version history
  • Version 1 (March 1, 1968): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts